Dual Biological Therapy for Ulcerative Colitis with Intractable Pyoderma Gangrenosum
- Author:
Hae Chan LEE
1
;
Yiyoung KWON
;
Eun Sil KIM
;
Soomin AHN
;
Yon Ho CHOE
;
Mi Jin KIM
Author Information
- Publication Type:Case Report
- From:Annals of Dermatology 2023;35(Suppl1):S107-S111
- CountryRepublic of Korea
- Language:English
- Abstract: Pyoderma gangrenosum is one of the dermatological extra-intestinal manifestations of ulcerative colitis (UC). We report a case of a 26-year-old male patient suffering from relapsed UC with a newly developed pyoderma gangrenosum. His skin and intestinal symptoms were intractable to treatment with steroids, immunosuppressants, or a single biological agent such as infliximab, golimumab, or vedolizumab. For the first time in Korea, we report a successful treatment experience of pyoderma gangrenosum in UC using dual biological agents, vedolizumab and infliximab. We strategically targeted each of the intestinal and skin symptoms, with a specific biological agent based on the drug’s mechanism of action.
